CORDIS · 731532 · H2020
ReGenHeart Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina A phase II randomized, double-blinded, placebo-controlled study
Coordinator: POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA (FI)
Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (<4%) thus refractory angina patients suffer multiple hospitalizations and low levels of health-related quality of life.The ReGenHeart project is based on extensive preclinical work and a phase I safety, feasibi…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €5.9M awarded to the consortium. The project runs over approximately 6 years from 2017-01-01 to 2022-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from FI
see all →- BalticSeaH2 — Cross-border Hydrogen Valley around the Baltic Sea101112047 · HORIZON · €25.0M
- R4C — Regions4Climate101093873 · HORIZON · €24.5M
- LUMI-IQ — LUMI AI Factory - Advanced experimental AI-optimised quantum based platform101239031 · HORIZON · €20.0M
- SPARCs — Sustainable energy Positive & zero cARbon CommunitieS864242 · H2020 · €19.7M
- Qu-Pilot — Experimental production capabilities for quantum technologies in Europe101113983 · HORIZON · €19.0M
- EUDAT2020 — EUDAT2020654065 · H2020 · €18.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €5.9M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-SC1-2016-2017.
- Who coordinates the project?
- The project is coordinated by POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA (FI).
- What is the project timeline?
- The project runs from 2017-01-01 to 2022-12-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 731532.